# US 2015/0174267 A1 · Compositions and methods for the transport of therapeutic agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0174267 A1
- Document ID: US20150174267A1
- Status: Published application
- Kind: A1
- Application number: 14/640,802
- Filed: 2015-03-06
- Published: 2015-06-25
- Earliest claimed: 2009-10-06
- Assignees: Angiochem Inc.
- Applicants: Angiochem Inc.
- Inventors: Jean-Paul CASTAIGNE; Michel Demeule; Christian Che; Anthony Regina
- Web page: https://patentgrep.com/patent/US20150174267A1

## CPC

- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/6907: {the form being a microemulsion, nanoemulsion or micelle}
- A61K 47/6911: {the form being a liposome}
- A61K 47/6921: {the form being a particulate, a powder, an adsorbate, a bead or a sphere}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/083: {Neurotensin}
- C07K 14/475: Growth factors; Growth regulators
- C07K 14/5759: {Products of obesity genes, e.g. leptin, obese (OB), tub, fat}
- C07K 14/8117: {Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention is directed to conjugates that include a polypeptide capable of crossing the blood-brain barrier or entering one or more cell types attached to a transport vector, i.e., a composition capable of transporting an agent (e.g., a therapeutic agent). In certain cases, the polypeptides are directly conjugated to a lipid or polymeric vector to allow targeted application of a therapeutic agent to treat, for example, a cancer, a neurodegenerative disease, or a lysosomal storage disorder.

## Claims

### Claim 1

A compound comprising a polypeptide and a transport vector, wherein:
(A) said polypeptide:
(a) comprises an amino acid sequence having at least 70% sequence identity to the sequence of SEQ ID NO:97 or to any of the sequences set forth in SEQ ID NOS:1-93, 98-105, and 107-116; and
(b) is conjugated to said transport vector, or
(B) said compound comprises the formula: A-X-B, wherein:
(a) A is a polypeptide comprising an amino acid sequence having at least 70% sequence identity to the sequence of Angiopep-2 (SEQ ID NO:97) or of SEQ ID NOS:1-93, 98-105, and 107-116;
(b) X is a linker; and
(c) B is a transport vector.

### Claim 2 (depends on 1)

The compound of claim 1, wherein said amino acid sequence identity is at least 90%.

### Claim 3 (depends on 1)

The compound of claim 1, wherein said polypeptide comprises the amino acid sequence set forth in one of SEQ ID NOS:67, 97, 107, 108, 109, 111, and 112.

### Claim 4 (depends on 1)

The compound of claim 1, wherein said polypeptide or said compound is able to cross the blood-brain bather in a mammal.

### Claim 5 (depends on 1)

The compound of claim 1, wherein said polypeptide is 10 to 50 amino acid residues in length.

### Claim 6 (depends on 1)

The compound of claim 1, wherein said transport vector is a lipid vector, a nanoparticle, a polyplex, or a dendrimer.

### Claim 7 (depends on 1)

The compound of claim 1, wherein said polypeptide is conjugated to said transport vector through a tether molecule or wherein X is a tether molecule.

### Claim 8 (depends on 7)

The compound of claim 7, wherein said tether molecule is a hydrophilic polymer.

### Claim 9 (depends on 1)

The compound of claim 1, wherein said polypeptide is conjugated to said transport vector by a hydrophobic bond or a covalent bond.

### Claim 10 (depends on 1)

The compound of claim 1, wherein said transport vector is bound to or contains a therapeutic agent.

### Claim 11 (depends on 10)

The compound of claim 10, wherein said therapeutic agent is a polynucleotide, a small molecule, an anticancer agent, a polypeptide, or a hydrophobic agent.

### Claim 12 (depends on 11)

The compound of claim 11, wherein said anticancer agent is paclitaxel, etoposide, doxorubicin, vinblastine, vincristine, cyclophosphamide, taxotere, melphalan, chlorambucil, or an analog thereof.

### Claim 13 (depends on 11)

The compound of claim 11, wherein said polynucleotide is an RNAi agent or encodes an RNAi agent.

### Claim 14 (depends on 13)

The compound of claim 13, wherein said RNAi agent is a short interfering RNA molecule (siRNA), an short hairpin RNA molecule (shRNA), a double stranded RNA molecule (dsRNA), or a microRNA molecule (miRNA).

### Claim 15 (depends on 14)

The compound of claim 14, wherein said RNAi agent is capable of inhibiting expression of protein involved in cancer or a neurodegenerative disease.

### Claim 16 (depends on 15)

The compound of claim 15, wherein said neurodegenerative disease is Parkinson's disease, Alzheimer's disease, dementia with Lewy bodies, or multiple system atrophy.

### Claim 17 (depends on 14)

The compound of claim 14, wherein said RNAi agent inhibits or silences expression of α-synuclein, α-secretase, BACE-1, γ-secretase, amyloid precursor protein (APP), epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR), sorting nexin-6 (SNX6), LINGO-1, Nogo-A, Nogo receptor 1 (NgR-1), superoxide dismutase 1 (SOD-1), Huntingtin (Htt), or platelet-derived growth factor receptor (PDGFR).

### Claim 18 (depends on 14)

The compound of claim 14, wherein said siRNA molecule comprises a nucleotide sequence having at least 90% sequence identity to any of the sequences set forth in SEQ ID NOS: 117-129.

### Claim 19 (depends on 11)

The compound of claim 11, wherein said polynucleotide encodes a protein that is deficient in a lysosomal storage disease.

### Claim 20 (depends on 19)

The compound of claim 19, wherein said polynucleotide encodes a protein selected from the group consisting of α-L-iduronidase, iduronate sulfatase, heparan N-sulfatase, α-N-acetylglucosaminidase, acetyl-CoA:α-glucosaminide acetyltransferase, N-acetylglucosamine 6-sulfatase, N-acetylgalactosamine 4-sulfatase, β-glucuronidase, sphingomyelinase, glucocerebrosidase, α-galactosidase-A, ceramidase, galactosylceramidase, arylsulfatase A, glial fibrillary acidic protein, aspartoacylase, phytanoyl-CoA hydroxylase, peroxin-7, β-galactosidase, β-hexosaminidase A, aspartylglucosaminidase (AGA), fucosidase, α-mannosidase, and sialidase.

### Claim 21 (depends on 11)

The compound of claim 11, wherein said polypeptide is selected from the group consisting of a GLP-1 agonist, leptin, neurotensin, glial-derived neurotrophic factor (GDNF), and brain-derived neurotrophic factor (BDNF), or an analog thereof.

### Claim 22 (depends on 1)

A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 23 (depends on 22)

A method of treating a subject having a neurodegenerative disease comprising administering to said subject the composition of claim 22 in a therapeutically effective amount.

### Claim 24 (depends on 23)

The method of claim 23, wherein said neurodegenerative disease is multiple sclerosis, schizophrenia, epilepsy, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), or a stroke.

### Claim 25 (depends on 22)

A method of treating a subject having a lysosomal storage disease comprising administering to said subject the composition of claim 22 in a therapeutically effective amount.

### Claim 26 (depends on 25)

The method of claim 25, wherein said lysosomal storage disease is mucopolysaccharidosis (MPS-I; i.e., Hurler syndrome or Scheie syndrome), MPS-II (Hunter syndrome), MPS-IIIA (Sanfilippo syndrome A), MPS-IIIB (Sanfilippo syndrome B), MPS-IIIC (Sanfilippo syndrome C), MPS-IIID (Sanfilippo syndrome D), MPS-VII (Sly syndrome), Gaucher's disease, Niemann-Pick disease, Fabry disease, Farber's disease, Wolman's disease, Tay-Sachs disease, Sandhoff disease, metachromatic leukodystrophy, or Krabbé disease.

### Claim 27 (depends on 22)

A method of treating a subject having a cancer comprising administering to said subject the composition of claim 22 in a therapeutically effective amount.

### Claim 28 (depends on 27)

The method of claim 27, wherein said cancer is in the brain or central nervous system (CNS) and wherein said cancer is a brain tumor, a brain tumor metastasis, or a cancer that has metastasized to the brain.

### Claim 29 (depends on 27)

The method of claim 27, wherein said cancer is a glioma, a glioblastoma, a hepatocellular carcinoma, or a lung cancer.

### Claim 30 (depends on 1)

A method of synthesizing the compound of claim 1, comprising conjugating a polypeptide comprising an amino acid sequence having at least 70% sequence identity to SEQ ID NO:97 or to any of SEQ ID NOS:1-93, 98-105, and 107-116 to a transport vector, wherein said polypeptide is exposed on the outer surface of said transport vector, or to a component of a transport vector or to a tether molecule conjugated to said component, thereby forming a conjugate, and forming a transport vector including said conjugate.
